A 66-year-old man presented with bilateral calf and thigh claudication brought on by walking less than half a block. With rest, the pain resolved within minutes. This discomfort was first noticed in the right leg 7 years ago and has become progressive and more disabling despite his following a standard walking program. He was unable to pursue his passion for golf because of this pain. He had no ischemic ulcerations or rest pain. His atherosclerotic risk factors included hypertension, cigarette smoking since the age of 15, and elevated total cholesterol level of 285 mg/dl. The hypertension (7 years' duration) was well controlled on enalapril and doxazosin. He also took levothyroxine for hypothyroidism induced after irradiation treatment of Graves' disease. Despite counseling he continued to smoke. Other associated medical conditions included polycythemia (controled with phlebotomy) and benign prostatic hypertrophy. There was no history of myocardial infarction, angina, congestive heart failure, TIAs or stroke.
aortoiliac disease ( Figure I) . Intra-arterial pressure gradients across the right and left iliac arteries were 90 mmHg and 70 mmHg respectively. Intravascular ultrasound confirmed the diffuse, extensive, calcific disease in both common and external iliac arteries.
Based on these data, it was elected to proceed with balloon angioplasty with primary stenting of both common iliac and left external iliac artery. Initially, the right common iliac occlusion was crossed with a hydrophilic guidewire using the contralateral approach. The wire was externalized through a retrograde right common femoral artery sheath (7 French) allowing for ipsilateral placement of the balloon and stents. One P394 Palmaz stcnt was deployed at the origin of each common iliac and expanded to 8 mm using a kissing-balloon technique (Figure 2a ). An additional Pl54 Palmaz stent was deployed in the distal right common iliac artery with minimal overlap to the initial stent. A separate P204 Palmaz stent was deployed in the proximal left external iliac artery and dilated to 7 mrn (Figure 2b) , maintaining flow patency of the left internal iliac artery. Postangioplasty, there were no residual pressure gradients ( Figure 3 ). There were also no procedural complications. The patient had excellent femoral and pedal pulses postprocedure and was discharged the following morning. Upon follow-up, his resting ankle/brachial indices were 0.93 on the right and 1.0 on the left. 
Discussion
Percutaneous transluminal angioplasty (PTA) for the treatment of atherosclerotic lesions has evolved rapidly over the past 30 years since Dotter and Judkins first described angioplasty in 1964.I Not only has there been a technical revolution. but the clinical application of these procedures has broadened. Balloon catheters continue to improve in durability, trackability and profile. The stronger plastic material used in the manufacture of balloons minimizes rupture on calcific plaques. This allows for higher inflation pressures while maintaining a consistent size, thus improving efficacy and safety. These materials can be wrapped more snuggly on to smaller catheters with stronger axial catheter strength, procuring access to previously unreachable lesions. Yet these catheters maintain enough flexibility to traverse the aortic bifurcation. facilitating contralateral angioplasty. Each stent has its own unique characteristics. For description. the Palmaz stent is a rigid. tubular, stainlesssteel stent that is balloon deployed and expanded (see Figure 2). It can be precisely placed, since it shortens minimally upon expansion. The stent struts are ideally imbedded into the atheroma of the vessel wall and it maintains good radial force or 'hoop' strength. Rigid stents seem to maintain radial strength better than do flexible stents, providing greater long-term vessel diameter.v' Re-endothelialization occurs within 6-8 weeks after implantation covering the exposed metal surface. Palmaz stents range in length from 10 mm to 39 mrn, with diameter expansion from 4 mm to 12 mm. Once deployed the Palmaz stent covers about 13% of the vessel wall surface area.'
The Wallstent is a flexible. multistrand mesh that is selfexpandable when implanted. The stent can be compatible with tortuous vessels; however, it shortens substantiaIly upon deployment making orificial placement. impr~cise. Once released, if maximal diameter is not obtained It can be further dilated with a balloon catheter. This stent is available in a variety of lengths (20-94 mm) and diameters (5-18 mm) , allowing a single stent to cover longer, more diffuse disease. It is unknown whether the flexibility in the stent stimulates intimal hyperplasia, but this seems to be a significant long-term problem. Flexible stents cover up to 30% of the vessel wall surface area.'
Which patients should be treated with endovascular techniques?
The American Heart Association Task Force on peripheral percutaneous transluminal angioplasty has reported guidelines to aid in stratifying angiographic findings with expected outcome.' Iliac artery atherosclerotic disease was divided into four categories depending on the severity of disease. Category I disease was defined as stenosis less than 3 em in length, concentric and noncalcified. PTA is the procedure of choice for such lesions with an expec~ed high technical/clinical success rate and low complication rate. Category 2 disease was defined as concentric stenos~s of 3-5 em, or eccentric, calcific stenoses less than 3 ern in length. These lesions are well suited for PTA. Category 3 disease was defined as an iliac stenosis 5-10 cm in length or occlusion less than 5 em in length after thrombolytic therapy with chronic symptoms. These lesions may be treated with PTA, but the extent of the lesions diminishes initial technical success and long-term durability. The patient's comorbid conditions for surgical repair should impact the treatment decision. Category 4 disease was defined as extensive bilateral iliac disease, with stenoses greater than 10 ern, and occlusions greater than 5 ern in length, or lesions adjacent to aortic aneurysmal disease. PTA has a limited role here, except for those patients for whom there is no surgical alternative because of low initial technical sucess, limited durability and higher complication rates. Unfortunately, the literature to date has not routinely evaluated iliac artery PTA based on these clinical categories.
Similar categories and guidelines outlining the specific application of intravascular stents have not been delineate~. Typically, stents have been deployed when balloon~ngl oplasty causes a flow-limiting intimal dissection, resldu~1 stenosis after PTA of > 30%, after successful thrombolysis of an iliac occlusion, or maximum trans-stenotic post-PTA pressure gradient after vasodilation of > 5 mmflg."
Anticipated results of PTA
Not only do many studies lack adherence to reporting standards, but they also lack functional evaluation and foIlowup. Tegtmeyer et al? reported on 200 patients (340 procedures) and showed an 80% patency rate at 4 years foIlow-up measured by improvement in clinica~grade only. The 60% patency rate on 667 iliac angioplasties fo.I1owed noninvasively at 4 years as reported by Johnston. s IS low, and does not account for femoral artery occlusions that occurred after iliac PTA. Data obtained from a meta-analy-
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Treatment (if iliac artery atherosclerosis 289 sis demonstrate a primary success rate of 92 l j( , with continued patency at I year of 91%, at 3 years of 80% and at 5 years of 72%.9 In summary, the initial technical failure rate is thought to be about 8-10% with additional failure of 10% during the first year, followed by 3% per year thereafter.
The predictors of long-term success or failure of PTA include extent of disease (focal versus diffuse), gender (male versus female), initial degree of ischemia (claudication versus rest pain or gangrene), location of the lesion (common iliac versus external iliac) and condition of the run-off." A residual pressure gradient after PTA is not a statisticaIly significant predictor of outcome or restenosis unless it is greater than 15 mmllg.!" Utilizing Cox regression analysis, patients with claudication rather than limb-threatening ischemia had a better patency rate with PTA (54% versus 48% at 5 years)." Likewise, when stenoses are compared with iliac occlusions, the l-year patency drops off substantially from 77% to 48%. When iliac occlusions were pretreated with intra-arterial thrombolytic therapy prior to PTA, the technical success rate improved from 48% to 96%." Common iliac artery PTA is more durable than is external iliac artery PTA (58% versus 46% at 5 years). This difference was even more pronounced in women, with only 34% patency rate at 5 years." The explanation for this gender difference may be the smaller size of the vessel, often requiring a 6 rnm balloon in women compared with a 7 to 8 mm baIloon in men. Poor run-off, defined as > 50% stenosis in the superficial femoral artery, negatively influenced iliac artery PTA patency at 5 years (57% good run-off versus 45% poor run-off)." Generally. the ideal iliac lesion for PTA is a short, focal. nonostial, concentric stenosis. Lesions that are diffuse, calcific, ostial, eccentric or longer than 3 em fare less well. Perhaps it is in these patients that the use of intravascular stents can improve results.
Do stents make a difference?
Clearly, stents improve upon the initial technical success rate of PTA. which rises from 91% to 97%.7.12.13 Stents compress flow-limiting intimal dissections and resolve resting pressure gradients.":" Noeldge, Richter and colleagues":" demonstrated in a randomized, comparative trial between primary iliac artery stenting and angioplasty that the residual pressure gradient was 6.3 mmHg with PTA, but 1.6 mmHg after stent placement (p < 0.00 I). The clinical significance of this finding is unknown. Not only did the stent patients show improved hemodynamic results, but also demonstrated improved early and long-term clinical success and angiographic patency. The clinical success rate at 60 months was 89.3% in the stented group versus 68.3% in the PTA group (p < 0.005). The nonstent patients had a reintervention rate of 28% at 36 months, but the rate in the stented group was unreported. Clinical success was defined as a sustained improvement in at least one clinical category of limb ischemia. It is unclear how many patients actually underwent angiographic re-evaluation.'?
In contrast, Palmaz et al'2 reported a clinical success rate in 486 iliac stent patients of 67%, 43 months after treatment. They surmised that progressive atherosclerotic disease, not necessarily in the stented segment, decreased sue-cess and occurred at a rate of 5% per year." The reintervention rate in this study was 2% at 36 months. Furthermore, Murphy et al" reported a 12.5% occlusion rate with Palmaz iliac stents at 10 months follow-up in 108 limbs, with only 37.5% of patients undergoing angiographic re-evaluation. Factors with negative prognostic significance included: multilevel (iliac and superficial femoral artery) disease, female gender, and pretreatment symptoms of limb at risk. No statistically significant difference was seen in common versus external iliac disease or diffuse disease confined to the iliac system. 12. 15 The implication here is that Palmaz stents may be superior to PTA alone in patients with external iliac disease or diffuse disease.
Wallstents have also shown encouraging results when deployed in iliac stenoses. The primary and secondary clinical patency rates were 81% and 91 %, respectively, at I year, but dropped to 71% and 86% at 2 years. 13 In the 66% of patients who had follow-up arteriography, the 6-month occlusion rate was 7%. Seventy-seven per cent of patients were claudicators. Ten per cent of patients in this study underwent reintervention.l! No statistical difference was seen when comparing common iliac and external iliac stent patencies. IS Therefore Wallstents also have a significant role in the treatment of external iliac artery stenoses. Since the Wallstent is flexible and available in longer lengths than the Palmaz stent, it may be more applicable in diffuse, complex iliac disease.
The safety of PTA and stents
The overall complication rate for aortoiliac PTA obtained from multiple studies was 8.1%.9 These complications infrequently result in a worsening of the patient's vascular status (3.8%), or death (0.3%). Most complications arise from the access site with hematoma or pseudoaneurysm formation, few of which require surgical correction. Arterial rupture and distal embolism are rare when treating stenotic (0.3%) iliac lesions, but increase in frequency when treating occlusions (3.1 %). 19 Stent complication rates are higher than with PTA alone. The Palmaz stent multicenter experience reported an overalI complication rate of 9.9% in 486 patients.'? and the Wallstent trial noted a 4.3% major and 10.7% minor complication rate.':' Vascular access site bleeding accounts for many of the complications and may be partly attributable to larger introducer sheaths required for stent delivery. For instance, iliac artery PTA (8 mm balIoon size) can frequently be performed through a 5 to 6 French (1.67-2.0 mm) sheath, whereas smalI Palmaz stents and WalIstents require at least a 7 French (2.3 mm) sheath. Larger stents sometimes even require 9 French (3.0 mm) sheaths. Iliac stent patients gen-eralIy do not require anticoagulation after intervention, which may influence the risk of postprocedure access site bleeding.
Specific complications associated with stents include: migration, inaccurate delivery, unpredictable expansion, restenosis secondary to intimal hyperplasia, and thrombosis. The immediate stent complications are usualIy quite manageable, producing infrequent need for surgical rescue. However, restenosis and thrombosis are problematic with current stent designs. Restenosis may be more evident when stents are underdeployed and not imbedded into the vessel Vascular Medicine 1996; 1: 287-291 walI. This favors formation of fibrin and thrombus lining of the stent, minimizing the usual re-endothelialization. Further thrombus propagation can lead to acute thrombosis or secondary formation of intimal hyperplasia." Significant stent restenosis is seen in at least 5% of patients with Palmaz stents and 10% of patients with Wallstents.P:" This restenosis rate is influenced by the postangioplasty diameter; consequently, the more the vessel is able to be dilated, the less frequent is the restenosis.P Significant restenosis will lead to higher reintervention rates escalating the overall cost of endovascular therapy.
Intravascular ultrasound (IVUS) greatly augments the angiographic images in the iliac vasculature. Not only can IVUS detect the presence and extent of disease, but it can also aid in sizing of the artery prior to dilation and stenting. Following stent placement, IVUS evaluates better the degree of deployment and how welI the stent is imbedded into the arterial wall."
Approach to the patient
All patients with atherosclerotic disease should be treated medically with aggressive risk factor modification, smoking cessation and a regular daily walking program. The indications for intervention on symptomatic patients include:
lifestyle-limiting claudication, ischemic rest pain, or ischemic ulceration/gangrene. In order to select appropriately the best revascularization alternative, one needs to be familiar with the surgical and nonsurgical options, the associated morbidity for each procedure and the underlying medical condition of the patient. In general, endovascular procedures carry a lower risk and short-term cost, but lack the durability of the surgical alternative.
The case description involved the treatment of diffuse, common and external iliac disease (category 3). Endovascular treatment was the preferred initial approach because of the patient's nonlimb-threatening clinical status. Palmaz stents were placed orificially in short segments, taking advantage of their radial strength. Primary stent deployment was chosen to perhaps prevent distal embolization, since thrombolytic therapy was not utilized pre-PTA.
When appropriately performed, iliac artery angioplasty can be technically easy because of the large caliber and flow characteristics of the vessel and proximity to the common femoral access site. Focal common iliac disease should be treated with PTA initially. If any significant residual resting pressure gradient remains after PTA then an intravascular stent should be deployed. Primary stenting should be performed with external iliac artery disease. Diffuse, orificial iliac stenoses, or iliac occlusions, when managed percutaneously, should be stented. Refinements in endovascular catheter interventions will continue to evolve, further expanding the application of these procedures.
